Intelligence / Healthtech / PMA Approvals / Edwards Lifesciences, LLC
Edwards Lifesciences, LLC
27 Oct 2026: Device change approved (PMA) · SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent. Recorded in the openFDA device PMA data.
- Decided
- 27 Oct 2026
- Device
- SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
- Specialty
- Cardiovascular
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Change Design/Components/Specifications/Material
- Reference
- P200015 S077
- Location
- Irvine, CA
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Find the decision makers at Edwards Lifesciences, LLC
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Edwards Lifesciences, LLC in our registers.
More in Cardiovascular
PMA Approvals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.